



21st May 2020

To,

BSE LIMITED

Phiroze Jeejeebhoy Towers

Dalal Street

Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, 5th Floor, Plot No. C/1, G Block

Bandra-Kurla Complex, Bandra (East)

Mumbai – 400051

Dear Sirs,

Discontinuation of supply of Ranitidine products

Pursuant to Clause 30 of the Listing Obligations and Disclosure Requirements Regulations, 2015 (LODR), we wish to inform you the following:

As previously communicated on 25 September 2019, GSK was contacted by regulatory authorities regarding the detection of NDMA in Zantac (ranitidine) products. Based on the information received and correspondence with regulatory authorities, the company made the decision in September 2019 and extended it in October 2019, to initiate a voluntary pharmacy/retail level recall in all markets of all Zantac products manufactured using all API sources, as a precautionary action. The recall also applied to all ranitidine products (Zinetac 150mg / 300mg Tablets) marketed by GSK in India. Further follow on disclosures in relation to the financial impact of the voluntary recall were also made on 3 February 2020.

GSK has continued to respond to the queries received from the regulatory authorities and to work actively with them to address their concerns. GSK has been conducting investigations into the potential source of the NDMA.

We are through this letter informing you that, subject to the approvals from the appropriate regulatory authorities, the Company has made a decision to discontinue the manufacture and supply of Zinetac tablets (150 mg and 300 mg products) manufactured in India and will in due course request cancellation of the marketing authorization(s) associated with Zinetac Tablets (150mg / 300mg). In the coming months, the Company will work closely with the regulatory authorities.

Patient safety remains the Company's utmost priority.

Kindly take the submission on record

Regards,

Thanking you,

Yours faithfully

For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni

Vice President – Administration, Real Estate

& Company Secretary